Exubera
insulin inhalation
Treatment for Diabetes Mellitus Type I, Diabetes Mellitus Type IIPfizer and the Sanofi-Aventis Group Seek Approval to Market Exubera in the United States
NEW YORK, March 02, 2005 -- Pfizer Inc and the Sanofi- Aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera (inhaled human insulin powder).
Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for over seven years.
The companies seek approval to market Exubera for adult patients with type 1 and type 2 diabetes. Exubera is currently also under review by the European Medicines Evaluation Agency.
It is estimated that nearly 180 million people worldwide suffer from diabetes, and the number is expected to rise to 300 million people in the next 20 years. More than half of people with diabetes remain uncontrolled or poorly controlled and are at risk for common complications such as heart disease, stroke, kidney failure, nerve damage and blindness. Currently, diabetes and its complications account for more than $100 billion in healthcare costs annually in the United States.
Exubera is being developed for patients with type 1 and type 2 diabetes through a collaboration between Pfizer and Sanofi-Aventis. The two companies have entered into a global agreement to co-develop, co-promote (where permitted by local law) and co-manufacture inhaled insulin. Pfizer is also in collaboration with Nektar Therapeutics, developers of the inhalation device and formulation.
About Pfizer
Pfizer discovers, develops, manufactures and markets leading
prescription medicines for humans and animals, and many of the
world's best known consumer products.
About Sanofi-Aventis
The Sanofi-Aventis Group is the world's 3rd largest pharmaceutical
company, ranking number 1 in Europe. Backed by a world-class
R&D organization, Sanofi-Aventis is developing leading
positions in seven major therapeutic areas: cardiovascular disease,
thrombosis, oncology, diabetes, central nervous system, internal
medicine, and vaccines. Sanofi-Aventis is listed in Paris and in
New York.
The Sanofi-Aventis Group conducts business in the United States through its affiliates Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc.
Related Articles:
Exubera Approved - Pfizer Inc - Treatment for Type 1 and Type 2 Diabetes in Adults - January 27, 2006
Pfizer and sanofi-aventis Statement on Status of Exubera - October 28, 2005
BioSante Encouraged by FDA Panel on Exubera, Superior Results of Own Inhaled Insulin Study - September 21, 2005
FDA Advisory Committee Recommends Approval of Exubera for Use in Adults With Type 1 and 2 Diabetes - September 8, 2005
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
